Beaujon Hospital / Hôpital Beaujon

Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment (2024) Overbeek KA, Poulsen JL, Lanzillotta M, Vinge-Holmquist O, Macinga P, Demirci AF, Sindhunata DP, et al. Journal article The use of deep learning models to predict progression-free survival in patients with neuroendocrine tumors (2023) Pavel ME, Dromain C, Ronot M, Schaefer N, Mandair D, Gueguen D, Elvira D, et al. Journal article Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors (2023) Dromain C, Pavel ME, Ronot M, Schaefer N, Mandair D, Gueguen D, Cheng C, et al. Journal article Standardization of the Definition and Surgical Management of Splenic Flexure Carcinoma by an International Expert Consensus Using the Delphi Technique: Room for Improvement? (2023) Benlice C, Parvaiz A, Baca B, Hohenberger W, Miskovic D, Stocchi L, Steele S, et al. Journal article Outcomes of rescue procedures in the management of locally recurrent ampullary tumors: A Pancreas 2000/EPC study (2023) Karam E, Hollenbach M, Ali EA, Auriemma F, Gulla A, Heise C, Regner S, et al. Journal article Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres (2022) Zandee WT, Merola E, Poczkaj K, de Mestier L, Klümpen HJ, Geboes K, de Herder WW, Munir A Journal article Lu-177-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial (2021) Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, et al. Journal article Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results (2021) Pavel ME, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, et al. Journal article The Phase 3 NETTER-1 Study of [Lu-177]Lu-DOTA-TATE in Patients with Midgut Neuroendocrine Tumours: Final Overall Survival and Long-Term Renal Safety (2021) Kunz P, Caplin ME, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, et al. Conference contribution Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability (2021) Dromain C, Sundin A, Najran P, Vidal Trueba H, Dioguardi Burgio M, Crona J, Opalinska M, et al. Journal article